基线18F-氟妥福司他PET骨肿瘤体积对接受177Lu-PSMA靶向放射配体治疗的转移性去势抵抗性前列腺癌患者严重血液学毒性的预后影响
本回顾性分析纳入182例接受[177Lu]Lu-PSMA-I&T治疗的mCRPC患者,评估基线18F-flotufolastat PET骨肿瘤指标对严重血液学毒性的预后价值。基线骨肿瘤体积可预测白细胞减少(每100 ml HR 1.03,p=0.036),骨病灶数目可预测贫血(每10个病灶HR 1.04,p<0.001)和严重贫血(每10个病灶HR 1.05,p=0.009);基线血红蛋白较高与白细胞减少、血小板减少和严重贫血风险降低相关;基线肾功能不全与贫血和严重贫血相关;既往[223Ra]氯化镭治疗可预测严重血小板减少。
要点
- 基线骨肿瘤体积每增加100 ml,白细胞减少风险HR 1.03(p=0.036)。
- 骨病灶每增加10个,贫血HR 1.04(p<0.001),严重贫血HR 1.05(p=0.009)。
- 既往[223Ra]氯化镭治疗者严重血小板减少HR 6.43(p=0.021)。
核心结论
- 基线18F-flotufolastat-PET骨肿瘤指标和治疗前临床参数是接受[177Lu]Lu-PSMA-I&T治疗的mCRPC患者严重血液学毒性的关键预后因素。
研究设计与样本
- 回顾性分析纳入182例有基线18F-flotufolastat-PET扫描和完整血液学资料的mCRPC患者,骨病灶采用半自动勾画。
- 血液学不良事件按不良事件通用术语标准5.0版定义,3-4级视为严重;采用Cox回归识别预后因素。
主要发现
- 基线骨肿瘤体积预测白细胞减少(每100 ml HR 1.03,p=0.036)。
- 骨病灶数目预测贫血(每10个病灶HR 1.04,p<0.001)和严重贫血(每10个病灶HR 1.05,p=0.009)。
- 基线血红蛋白较高与白细胞减少(HR 0.74,p=0.002)、血小板减少(HR 0.80,p=0.033)和严重贫血(HR 0.52,p<0.001)风险降低相关。
- 基线肾功能不全与贫血(HR 2.46,p=0.002)和严重贫血(HR 3.81,p=0.023)相关。
- 既往[223Ra]氯化镭治疗预测严重血小板减少(HR 6.43,p=0.021)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This retrospective analysis evaluated the prognostic value of baseline 18F-flotufolastat-PET bone tumor metrics for severe hematologic toxicity in metastatic castration-resistant prostate cancer (mCRPC) patients treated with [177Lu]Lu-PSMA-I&T. METHODS: Data from 182 mCRPC patients with baseline 18F-flotufolastat-PET scans and complete hematologic profiles were analyzed. Bone lesions were semiautomatically delineated, and clinical parameters (e.g., pretreatments, lab results) were assessed. Hematologic adverse events (AEs) were defined per Common Terminology Criteria for Adverse Events version 5.0, with grades 3-4 considered severe. Cox regression was used to identify prognostic factors for AEs. RESULTS: Baseline bone tumor volume prognosticated leukocytopenia (HR 1.03 per 100 ml, p = 0.036), while the number of bone lesions was prognostic for anemia (HR 1.04 per 10 lesions, p < 0.001) and severe anemia (HR per 10 lesions 1.05, p = 0.009). Higher baseline hemoglobin correlated with reduced leukocytopenia (HR 0.74, p = 0.002), thrombocytopenia (HR 0.80, p = 0.033), and severe anemia (HR 0.52, p < 0.001). Baseline kidney dysfunction was linked to anemia (HR 2.46, p = 0.002) and severe anemia (HR 3.81, p = 0.023). Prior [223Ra]Radiumdichloride treatment prognosticated severe thrombocytopenia (HR 6.43, p = 0.021). CONCLUSION: Baseline 18F-flotufolastat-PET metrics and pretherapeutic clinical parameters are key prognostic factors for severe hematologic toxicity in mCRPC patients treated with [177Lu]Lu-PSMA-I&T.
引用
- Karimzadeh A, Hansen K, Hein S, et al. Impact of baseline 18F-flotufolastat PET bone tumor volume for prognosticating severe hematologic toxicity in patients with metastatic castration-resistant prostate Cancer receiving 177Lu-PSMA-targeted radioligand therapy. Eur J Nucl Med Mol Imaging. 2025. PMID: 40383857. doi:10.1007/s00259-025-07200-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。